A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects

Braintree Laboratories

Status and phase

Completed

Phase 2

Conditions

Constipation

Treatments

Drug: BLI400 Laxative

Study type

Interventional

Funder types

Industry

Identifiers

NCT02665728

BLI400-201

Details and patient eligibility

About

The objective of this study is to evaluate the safety and efficacy of BLI400 laxative in constipated adolescent subjects.

Enrollment

33 patients

Sex

All

Ages

12 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female subjects at between 12-17 years of age
Weight more than 40 kg (88 lbs.).
Constipated, defined by the following criteria
1. Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months:
  1. Straining during > 25% of defecations
  2. Lumpy or hard stools in > 25% of defecations
  3. Sensation of incomplete evacuation for > 25% of defecations
2. Loose stools are rarely present without the use of laxatives
3. There are insufficient criteria for irritable bowel syndrome - loose (mushy) or watery stool in the absence of laxative use for more than 25% of bowel movements

Criteria A, B and C must be fulfilled for the last 12 weeks with symptom onset at least 6 months prior to diagnosis.

Otherwise in good health, as determined by physical exam and medical history
If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intrauterine device, double-barrier method, depot contraceptive, sterilized, or abstinence)
Negative urine pregnancy test at screening, if applicable
In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion criteria

Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1
Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1
Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 3
Subjects who are pregnant or lactating, or intend to become pregnant during the study
Subjects of childbearing potential who refuse a pregnancy test
Subjects who are allergic to the study medication
Subjects taking narcotic analgesics or other medications known to cause constipation
Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
Subjects with an active history of drug or alcohol abuse
Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1
Subjects who withdraw consent at any time prior to completion of Visit 1 procedures